Mohammad Vaziri Shares Breakthrough Insights on Factor XI Inhibitors for Thrombosis Prevention and Safer Anticoagulation
Mohammad Vaziri, Thoracic Surgery Professional at IRAN University of Medical Sciences (IUMS), posted on LinkedIn:
”Key points
Factor XI (FXI) inhibitors aim to uncouple hemostasis from thrombosis, presenting a novel approach to anticoagulation, with a reduced risk of bleeding compared with that associated with traditional anticoagulant agents.
Several phase II studies indicate that FXI inhibitors decrease thrombotic complications dose-dependently, without corresponding increases in bleeding, suggesting a favourable safety profile.
FXI inhibitors showed non-inferiority and potential superiority to low-molecular-weight heparin for the prevention of venous thromboembolism in patients undergoing orthopaedic surgery, with minimal bleeding risks observed at therapeutic doses.
Milvexian and abelacimab are theoretically promising for reducing the risk of bleeding associated with thromboprophylaxis in patients with atrial fibrillation; phase III clinical trials of safety and efficacy are ongoing.
In phase II trials involving patients with non-cardioembolic ischaemic stroke, no significant benefit of FXI inhibitors was found in terms of the primary ischaemic end points, but future phase III trials might find benefits in selected patients with large-vessel atherosclerosis.
The ongoing LIBREXIA-ACS trial will assess the use of milvexian in 16,000 patients with recent acute coronary syndrome.”
Reaf the full article here.
Title: Factor XI inhibitors for the prevention and treatment of venous and arterial thromboembolism
Authors: Davide Capodanno, John H. Alexander, M. Cecilia Bahit, John W. Eikelboom, C. Michael Gibson, Shaun G. Goodman, Vijay Kunadian, Gregory Y. H. Lip, Renato D. Lopes, Roxana Mehran, Shamir R. Mehta, Manesh R. Patel, Jonathan P. Piccini, Sunil V. Rao, Christian T. Ruff, P. Gabriel Steg, Jeffrey I. Weitz, Dominick J. Angiolillo
Stay updated with Hemostasis Today.
-
Nov 15, 2025, 12:24Thomas Reiser: Can AI Keep Up with Thrombosis Specialists?
-
Nov 15, 2025, 12:13Michael Makris on Immediate Suspension of Use of Plasma Derived FIX Concentrates in Punjab
-
Nov 15, 2025, 09:32Tushar Pandey: Hounoured to Be Part of Hematocon 2025
-
Nov 15, 2025, 09:11Lisa Murphy invites You to Join Her at Stroke Foundation’s Run4Stroke Marathon
-
Nov 15, 2025, 08:56Ahmed Bennis on Potential Use of P2Y12 Inhibitors as Safer Alternative in Monotherapy
-
Nov 15, 2025, 08:39Marika Nöjd: Donating Blood is An Easy Way to Do Good!
-
Nov 15, 2025, 08:19Joseph Caprini Released His UIP 2025 Session on VTE Recurrence Risk
-
Nov 15, 2025, 07:14Paul Bolaji Invites You to ”Thrombolytic Therapy in Acute Stroke in African Patients” Seminar
-
Nov 15, 2025, 07:03Carla Goulart Peron Explores The Role of Technology and Collaboration in Global Stroke Action